Marcaine Spinal 0,5 % Heavy (Bupivacaine Hydrochloride)

Bupivacaine blocks voltage‑gated sodium channels on peripheral and central nerve fibers. By stabilizing the inactive channel state, it prevents the influx of sodium ions required for depolarisation, thereby halting the generation and propagation of nerve impulses. This results in reversible loss of sensation and motor function in the area supplied by the blocked nerves.

The specific intrathecal volume and concentration are determined by the prescribing clinician based on the type of surgery, patient characteristics and desired block level. Only a qualified healthcare professional should calculate and administer the dose; no standard dose is provided here.

Bupivacaine is classified as pregnancy category C, indicating that risk to the fetus cannot be ruled out and the drug should be used only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding, and the decision should be made by the treating physician after evaluating maternal and infant safety.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After verification, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

The most common alternative for spinal anesthesia is ropivacaine, another long‑acting amide local anesthetic. Compared with ropivacaine, bupivacaine generally provides a slightly longer duration of block but has a higher potential for cardiotoxicity at supratherapeutic concentrations. Choice between them depends on the clinical scenario, required block duration and patient‑specific safety considerations.

The product should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze the solution, and ensure the vial is kept upright to avoid agitation of the suspension before use.

Administration is performed by a qualified anesthesiologist or trained practitioner. After aseptic preparation, a small gauge spinal needle is inserted into the lumbar subarachnoid space, and the calculated volume of the 0.5 % bupivacaine solution is injected slowly. The patient is then positioned to allow the desired spread of the anesthetic.

Serious adverse events include high spinal block leading to respiratory compromise, cardiac arrhythmias such as ventricular tachycardia, and rare neurotoxicity that may result in persistent neurologic deficits. Prompt recognition and supportive management are essential, and patients should be continuously monitored for hemodynamic and neurologic changes during and after the block.

Contraindications include patients with known hypersensitivity to bupivacaine or other amide local anesthetics, those with severe hypovolemia, uncorrected coagulopathy, infection at the injection site, or significant cardiac conduction disorders. Caution is also advised in patients with severe aortic stenosis, elevated intracranial pressure, or uncontrolled epilepsy.